Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease
Use of SGLT2 inhibitors was associated with a lower incidence of biochemical abnormalities related to CKD-MBD than GLP-1 RAs. These agents may be considered to reduce risk of CKD-MBD in patients with type 2 diabetes mellitus and stage 1-3 CKD.
Authors
- Kuan‐Hung Liu (ORCID: https://orcid.org/0000-0001-5988-6123)
- Edward Chia‐Cheng Lai (ORCID: https://orcid.org/0000-0002-5852-7652)
- Daniel Hsiang‐Te Tsai (ORCID: https://orcid.org/0000-0003-2841-0338)
- Shih‐Chieh Shao (ORCID: https://orcid.org/0000-0003-4867-6686)
- Albert Tzu-Ming Chuang
Institutions
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1503/cmaj.240922
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47